» Articles » PMID: 29608684

Microsphere Controlled Drug Delivery for Local Control of Tooth Movement

Overview
Journal Eur J Orthod
Specialty Dentistry
Date 2018 Apr 3
PMID 29608684
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Because orthodontic tooth movement is dependent upon osteoclast-mediated resorption of alveolar bone adjacent to the pressure side of tooth roots, biologic mediators that regulate osteoclasts can be utilized to control tooth movement.

Objectives: To develop a novel method to locally enhance orthodontic anchorage.

Methods: We encapsulated osteoprotegerin (OPG) in polymer microspheres and tested the effectiveness of microsphere encapsulated versus non-encapsulated OPG for enhancing orthodontic anchorage in a rodent model of tooth movement. A single injection of 1 mg/kg non-encapsulated or microsphere encapsulated OPG was delivered into the palatal mucosa mesial to the first maxillary molar 1 day prior to tooth movement. A positive control group received injections of 5 mg/kg non-encapsulated OPG every 3 days during tooth movement. After 28 days of tooth movement, hemi-maxillae and femurs were dissected. Molar mesial and incisor distal tooth movement was measured using stone casts that were scanned and magnified. Local alveolar, distant femur bone, and tooth root volumes were analyzed by micro computed tomography. Serum OPG levels were measured by ELISA. Osteoclast numbers were quantified by histomorphometry.

Results: The single injection of microsphere encapsulated OPG significantly enhanced orthodontic anchorage, while the single injection of non-encapsulated OPG did not. Injection of encapsulated OPG inhibited molar mesial movement but did not inhibit incisor tooth movement, and did not alter alveolar or femur bone volume fraction, density, or mineral content. Multiple injections of 5 mg/kg non-encapsulated OPG enhanced orthodontic anchorage, but also inhibited incisor retraction and altered alveolar and femur bone quality parameters. Increased OPG levels were found only in animals receiving multiple injections of non-encapsulated 5 mg/kg OPG. Osteoclast numbers were higher upon tooth movement in animals that did not receive OPG. Osteoclast numbers in OPG injected animals were variable within groups.

Conclusions: Microsphere encapsulation of OPG allows for controlled drug release, and enhances site-specific orthodontic anchorage without systemic side effects. With additional refinements, this drug delivery system could be applicable to a broad array of potential biologic orthodontic therapeutics.

Citing Articles

Engineering approaches to manipulate osteoclast behavior for bone regeneration.

Cheng X, Tian W, Yang J, Wang J, Zhang Y Mater Today Bio. 2024; 26:101043.

PMID: 38600918 PMC: 11004223. DOI: 10.1016/j.mtbio.2024.101043.


Comparative Efficacy of Traditional Corticotomy and Flapless Piezotomy in Facilitating Orthodontic Tooth Movement: A Systematic Review and Meta-Analysis.

Han S, Park W, Park J Medicina (Kaunas). 2023; 59(10).

PMID: 37893522 PMC: 10608606. DOI: 10.3390/medicina59101804.


Functional Biomaterials for Local Control of Orthodontic Tooth Movement.

Lin Y, Fu M, Harb I, Ma L, Tran S J Funct Biomater. 2023; 14(6).

PMID: 37367258 PMC: 10299595. DOI: 10.3390/jfb14060294.


Control of Orthodontic Tooth Movement by Nitric Oxide Releasing Nanoparticles in Sprague-Dawley Rats.

Crawford D, Lau T, Frost M, Hatch N Front Dent Med. 2022; 9.

PMID: 36081866 PMC: 9451041. DOI: 10.3389/fmats.2022.811251.


Injectable RANKL sustained release formulations to accelerate orthodontic tooth movement.

Chang J, Chen P, Arul M, Dutra E, Nanda R, Kumbar S Eur J Orthod. 2019; 42(3):317-325.

PMID: 31147678 PMC: 7311078. DOI: 10.1093/ejo/cjz027.

References
1.
Hudson J, Hatch N, Hayami T, Shin J, Stolina M, Kostenuik P . Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability. Calcif Tissue Int. 2012; 90(4):330-42. DOI: 10.1007/s00223-012-9579-4. View

2.
Bekker P, Holloway D, Rasmussen A, Murphy R, Martin S, Leese P . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004; 19(7):1059-66. DOI: 10.1359/JBMR.040305. View

3.
Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

4.
REITAN K . The initial tissue reaction incident to orthodontic tooth movement as related to the influence of function; an experimental histologic study on animal and human material. Acta Odontol Scand Suppl. 1951; 6:1-240. View

5.
Body J, Greipp P, Coleman R, Facon T, Geurs F, Fermand J . A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003; 97(3 Suppl):887-92. DOI: 10.1002/cncr.11138. View